The U.S. Food and Drug Administration (FDA) has clarified which bulk drug substances may be used in human drug compounding under Section 503A of the Federal Food, Drug, and Cosmetic (FD&C) Act, a move that directly affects what customized medicines pharmacies can legally prepare for individual patients.
In an update described on FDA.gov under the heading “Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act,” the agency reiterates that compounders may only use bulk drug substances that meet one of three conditions: they must comply with an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph, be a component of an FDA‑approved drug, or appear on FDA’s 503A bulks list.
The clarification is aimed at traditional compounders — typically state‑licensed pharmacies, physicians, and certain hospital pharmacies — that prepare patient‑specific medications when commercially available drugs do not meet a medical need.
What the FDA has confirmed
According to the FDA’s 503A bulk substances page on FDA.gov, a bulk drug substance used in compounding under Section 503A must fit into at least one of the following categories:
USP or NF monograph compliance
The substance complies with the standards of an applicable USP or NF monograph, if one exists. A monograph is an official quality standard that describes a drug’s name, strength, quality, and purity tests.Component of an FDA‑approved drug
The substance is an active ingredient in at least one FDA‑approved drug product. This links its use in compounding to ingredients that have already undergone FDA review in an approved medicine.Inclusion on FDA’s 503A bulks list
The substance appears on the FDA’s list of bulk drug substances that may be used in compounding under Section 503A, sometimes referred to as the “503A bulks list.” The FDA maintains and updates this list through its own evaluation process.
The agency states that a compounder may only compound a drug using a bulk drug substance that satisfies at least one of these three criteria. Substances that do not meet any of them are not eligible for use in 503A compounding.
Why Section 503A matters for patients and pharmacies
Section 503A of the FD&C Act sets conditions under which certain compounded human drugs are exempt from key requirements that apply to conventional drug manufacturers, including FDA approval, labeling with adequate directions for use, and current good manufacturing practice requirements. In exchange for these exemptions, compounders must follow specific safeguards.
The FDA’s 503A bulk substances page explains that these safeguards include:
- Compounding only after receiving a valid prescription for an identified individual patient (with limited allowances for anticipatory compounding based on history and patterns of prescriptions).
- Using bulk drug substances that meet the quality and eligibility criteria described in the statute and FDA’s implementation of it.
By tying eligible bulk substances to USP/NF standards, FDA‑approved drug components, or the agency’s own bulks list, the FDA is attempting to limit compounding to ingredients with recognized quality benchmarks or prior regulatory scrutiny.
For patients, this framework is intended to preserve access to customized medicines — such as different dosage forms, strengths, or combinations not available commercially — while reducing the risk that compounded products are made from ingredients of uncertain quality or safety.
How the 503A bulks list works
On its 503A bulk substances page, the FDA describes the 503A bulks list as a specific list of bulk drug substances that it has evaluated for use in compounding under Section 503A. Only substances that the agency has decided to include on this list may be used under the third eligibility pathway.
The FDA explains that:
- Substances may be nominated for inclusion on the 503A bulks list.
- The agency evaluates nominated substances and decides whether to place them on the list, decline them, or defer a decision.
The details of each evaluation, including individual substance decisions, are not fully laid out in the brief public summary, but the agency’s description makes clear that being on the 503A bulks list is not automatic. It is the result of a specific FDA review process.
For compounders, this means:
- A bulk drug substance that does not have a USP or NF monograph and is not a component of an FDA‑approved drug can only be used if it appears on the 503A bulks list.
- If a substance is not on the list and does not meet either of the other two criteria, it is not eligible for compounding under 503A.
This structure creates a defined, but narrower, universe of substances that traditional compounders can draw from when preparing medications.
Implications for compounders and ingredient suppliers
The FDA’s 503A bulk substances page underscores that compounders are responsible for ensuring that any bulk drug substance they use is eligible under Section 503A.
In practical terms, this means a pharmacy or physician who compounds must:
- Verify whether a substance has an applicable USP or NF monograph and ensure compliance with that monograph.
- Determine whether the substance is a component of an FDA‑approved drug.
- Check whether the substance is listed on the FDA’s 503A bulks list if it does not qualify under the first two categories.
Bulk ingredient suppliers, including those based in India and other countries that export active pharmaceutical ingredients to the United States, can be affected by these requirements because their products must fit into at least one of the three eligibility routes to be used in 503A compounding. The FDA.gov material does not single out any specific country, but the rules apply regardless of where the bulk substance is manufactured.
The FDA’s description of the 503A framework also implies that compounders who use ineligible substances risk falling outside the statutory exemptions. In that case, their compounded products could be treated as unapproved new drugs subject to enforcement.
What is at stake for access and oversight
The FDA’s restatement of the three eligibility pathways for bulk substances under Section 503A highlights a central tension in compounding policy: balancing patient access to tailored medications with oversight of ingredient quality and safety.
From the perspective laid out on FDA.gov:
- The three‑pathway rule is designed to keep compounding anchored to ingredients with recognized standards or prior regulatory review.
- The 503A bulks list functions as a controlled gateway for additional substances that do not have monographs and are not part of approved drugs.
For patients who rely on compounded medicines — for example, those who cannot tolerate certain excipients (inactive ingredients) or who need non‑standard strengths — the FDA’s framework shapes which therapies their pharmacists can offer. For compounders and ingredient suppliers, it sets a clear but constrained regulatory boundary.
The FDA.gov material emphasizes compliance with these statutory conditions but does not provide detailed data on how many substances are currently on the 503A bulks list or how often nominations are accepted or rejected. Those details will help determine how restrictive the practical impact is on day‑to‑day compounding.
Why this clarification matters now
By clearly restating that only bulk drug substances that comply with a USP or NF monograph, are components of an FDA‑approved drug, or appear on the 503A bulks list may be used in 503A compounding, the FDA is signaling continued attention to the boundaries of traditional pharmacy compounding.
For readers, the key takeaway from the FDA.gov update is straightforward:
- Not every pharmaceutical ingredient on the market can be used in patient‑specific compounded medicines.
- Only substances that fit one of the three statutory pathways are eligible under Section 503A.
As the FDA continues to administer the 503A bulks list and enforce these criteria, patients and providers who depend on compounded drugs may see changes in which formulations are available, particularly when ingredients fall outside the three permitted categories. How pharmacies and suppliers adapt to these limits will shape the practical availability of customized treatments within the legal framework the FDA has described.
